Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -0.96%92.131.9%$1192.97m
JNJJohnson & Johnson -0.87%144.440.7%$1057.09m
BMYBristol-Myers Squibb Co. -0.57%60.791.0%$967.46m
PFEPfizer Inc. 0.64%37.500.9%$831.88m
MRKMerck & Co., Inc. -0.22%76.380.7%$796.50m
LLYEli Lilly & Co. -0.69%151.231.1%$417.06m
AZNAstraZeneca Plc -0.11%55.221.2%$261.94m
NVSNovartis AG -0.09%84.910.2%$156.50m
GSKGlaxoSmithKline Plc -0.37%40.880.2%$140.53m
NVONovo Nordisk A/S 0.05%64.850.1%$87.00m
SNYSanofi -0.30%47.300.2%$78.78m
RGENRepligen Corp. -0.57%139.517.1%$73.05m
ARCTArcturus Therapeutics Holdings, Inc. 7.71%58.270.0%$60.48m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 11.80%58.370.0%$42.40m
RETAReata Pharmaceuticals, Inc. 1.04%160.003.4%$38.83m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.